NCT02592174View on ClinicalTrials.gov

Prevalence, Characteristics and Risk Factors of HIV-Associated Neurocognitive Disorders in Subjects Between the Ages of 55 and 70 Years: An Exposed/Unexposed Cross Sectional Study

NACompletedINTERVENTIONAL
Enrollment

220

Participants

Timeline

Start Date

January 26, 2016

Primary Completion Date

October 27, 2017

Study Completion Date

October 27, 2017

Conditions
HIV-1 Infection
Interventions
OTHER

Health related quality of life and social and demographic informations

At the inclusion visit with a self-assessment questionnaire

OTHER

Neurocognitive assessment

At the neurocognitive visit, with standard test as CONSTANCES cohort

RADIATION

cerebral images sub-study

Standard magnetic resonance imaging

Trial Locations (6)

13274

Hôpial Sainte Marguerite - Service d'hématologie-Cisih, Marseille

30029

Hôpital Carémeau - Service des Maladies Infectieuses, Nîmes

34295

Hôpital Gui de Chauliac - Service des Maladies Infectieuses, Montpellier

37044

Hôpital Bretonneau - Service des Maladies Infectieuses, Tours

38043

Hôpital Michallon- Service des Maladies Infectieuses, Grenoble

06401

Centre Hospitalier de Cannes - Service de Médecine Interne Oncologie, Cannes

All Listed Sponsors
collaborator

Merck Sharp & Dohme LLC

INDUSTRY

lead

ANRS, Emerging Infectious Diseases

OTHER_GOV

NCT02592174 - Prevalence, Characteristics and Risk Factors of HIV-Associated Neurocognitive Disorders in Subjects Between the Ages of 55 and 70 Years: An Exposed/Unexposed Cross Sectional Study | Biotech Hunter | Biotech Hunter